SCHEMBL2929154

SCHEMBL2929154

Cc1ccn2c(C(=O)Cl)c(C)nc2c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.58
POLB P06746 3/20 0.58
SMN1; SMN2 Q16637 6/20 0.57
LMNA P02545 1/20 0.57
ALDH1A1 P00352 6/20 0.54
KDM4E B2RXH2 5/20 0.54
MAPT P10636 2/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
CGAS Q8N884 1/20 0.49
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768162 0.85 SMN1; SMN2 (0.61) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL6112657 0.85 KMT2A (0.64) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL19723534 0.84 GAA (0.58) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL10511369 0.83 POLB (0.64) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL20250793 0.81 POLB (0.66) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL17321417 0.81 GAA (0.55) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL6113039 0.80 POLB (0.64) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL19723588 0.80 GAA (0.68) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL1768201 0.79 RAB9A (0.69) GAAPOLBSMN1; SMN2LMNAALDH1A1
SCHEMBL2937795 0.79 KMT2A (0.73) GAAPOLBSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10913737-B2 Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2021-02-09 US disclosed
EP-3257854-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME University of Notre Dame du Lac (US) 2017-12-20 EP disclosed
US-9309238-B2 Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2016-04-12 US disclosed
US-9309238-B2 Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same UNIVERSITY OF NOTRE DAME DU LAC (US) 2016-04-12 US disclosed
US-20120220457-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME DOW AGROSCIENCES LLC (US) 2012-08-30 US disclosed
US-20120220457-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME DOW AGROSCIENCES LLC (US) 2012-08-30 US disclosed
WO-2011057145-A2 IMIDAZO[1,2-A] PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME UNIVERSITY OF NOTRE DAME DU LAC (US) 2011-05-12 WO disclosed
EP-1682549-B1 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR INC (US) 2010-09-22 EP disclosed
US-7723324-B2 Imidazo[1,2-A]pyridine anxiolytics SEPRACOR, INC. (US) 2010-05-25 US disclosed
US-7566725-B2 Imidazo[1,2-A] pyridine anxiolytics SEPRACOR INC. (US) 2009-07-28 US disclosed
US-20080096867-A1 Imidazo[1,2-A] Pyridine Anxiolytics SEPRACOR INC. (US) 2008-04-24 US disclosed
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS SEPRACOR INC. (US) 2007-02-22 US disclosed
US-7148353-B2 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2006-12-12 US disclosed
EP-1682549-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS Sepracor Inc. (US) 2006-07-26 EP disclosed
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2005-08-04 US disclosed
WO-2005044818-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR, INC. (US) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913737-B2 Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same RIF1, PYCR1, PNMT GAA 1646/4885POLB 3367/4885SMN1; SMN2 3108/4885
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS CNR1, CNR2, GABRA5 GAA 2781/4885POLB 4220/4885SMN1; SMN2 1946/4885
US-20120220457-A1 IMIDAZO [1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME RIF1, PYCR1, PNMT GAA 1646/4885POLB 3367/4885SMN1; SMN2 3108/4885
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics CNR1, CNR2, GABRA5 GAA 2781/4885POLB 4220/4885SMN1; SMN2 1946/4885
US-20080096867-A1 Imidazo[1,2-A] Pyridine Anxiolytics MTNR1B, ADORA2B, ADRA2B GAA 2658/4885POLB 1180/4885SMN1; SMN2 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.